Maxillary Mucormycosis Osteomyelitis in Post COVID-19 Patients: A Series of Fourteen Cases

Wael M Said Ahmed; Amira M Elsherbini; Nehal M Elsherbiny; Mohamed El-Sherbiny; Nevine I Ramzy; Ahmed F Arafa

doi:10.3390/diagnostics11112050

Maxillary Mucormycosis Osteomyelitis in Post COVID-19 Patients: A Series of Fourteen Cases

Diagnostics (Basel). 2021 Nov 5;11(11):2050. doi: 10.3390/diagnostics11112050.

Authors

Wael M Said Ahmed¹, Amira M Elsherbini², Nehal M Elsherbiny^{3

4}, Mohamed El-Sherbiny^{5

6}, Nevine I Ramzy⁷, Ahmed F Arafa⁸

Affiliations

¹ Oral and Maxillofacial Department, Faculty of Dentistry, Mansoura University, Mansoura 35516, Egypt.
² Oral Biology Department, Faculty of Dentistry, Mansoura University, Mansoura 35516, Egypt.
³ Department of Biochemistry, Faculty of Pharmacy, Mansoura University, Mansoura 35516, Egypt.
⁴ Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Tabuk, Tabuk 47512, Saudi Arabia.
⁵ Department of Basic Medical Sciences, College of Medicine, AlMaarefa University, Riyadh 71666, Saudi Arabia.
⁶ Department of Anatomy, Mansoura Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt.
⁷ Pathology Department, Faculty of Medicine, Cairo University, Giza 11562, Egypt.
⁸ Oral and Maxillofacial Department, Zagazig University, Zagazig 44519, Egypt.

Abstract

During the current pandemic of COVID-19, numerous manifestations and complications have developed. Patients with COVID-19 are at high risk of fungal infections, such as mucormycosis, that may result directly from COVID-19 infection and/or as a side effect of the drugs used in COVID-19 treatment protocol, such as dexamethasone, hydroxychloroquine, and antibiotics. In this report, we described a series of 14 cases with maxillary mucormycosis osteomyelitis in immediate post-COVID-19 patients.

Keywords: COVID-19; maxilla; mucormycosis; osteomyelitis.

Publication types

Case Reports